Helicobacter pylori (HP) infection has been proposed to influence treatment response and clinical outcomes in Parkinson’s disease (PD). Prior observational reports and mechanistic hypotheses have suggested that HP may alter absorption of dopaminergic medications or modulate the gut–brain axis. This trial sought to determine whether targeted eradication of HP would translate into measurable clinical benefits in people with PD.
This study was a double‑blind, randomized, placebo‑controlled trial. Adults with PD who tested positive for HP by urea‑breath testing were randomized in a 1:1 ratio to receive either a standard HP triple therapy regimen or matched placebo. The active regimen consisted of omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, each administered twice daily for 14 days. The trial methods reported adherence to ethical standards, including Institutional Ethics Committee approval, written informed consent, and compliance with the Declaration of Helsinki and ICH GCP guidelines.
Eighty participants underwent urea‑breath testing as part of screening. Thirty‑four tested positive for HP; of these, 30 individuals were randomized between the active eradication arm and placebo. The abstract does not provide additional participant characteristics (age distribution, PD duration, medication regimens, or baseline severity) beyond the numbers screened and randomized.
The primary outcome was the Movement Disorder Society‑Unified Parkinson’s Disease Rating Scale (MDS‑UPDRS) Part III motor score measured in the ON medication state at 12 weeks after randomization. Secondary endpoints included the total MDS‑UPDRS score, the Non‑Motor Symptoms Scale (NMSS) score, and health‑related quality of life measured by the Parkinson’s Disease Questionnaire‑39 (PDQ‑39) summary index. The trial planned analysis comparisons between the eradication and placebo groups at the 12‑week time point; adjustment for baseline scores was reported for the primary outcome.
The primary analysis found no statistically significant difference between groups in the MDS‑UPDRS Part III motor score at 12 weeks. The reported between‑group mean difference was −3.9 points (95% CI −15.5 to 7.6; p = 0.49). Adjustment for baseline scores did not yield a significant effect (adjusted p = 0.13).
Secondary outcomes also showed no significant differences. The total MDS‑UPDRS score had a mean difference of −0.13 (95% CI −22.1 to 21.8; p = 0.99). The NMSS score difference was 23.3 (95% CI −8.8 to 55.4; p = 0.15). PDQ‑39 summary index scores differed by −7.1 (95% CI −35.4 to 21.1; p = 0.61). All reported p values indicate lack of statistical evidence that HP eradication improved motor function, non‑motor symptom burden, or quality of life at the 12‑week assessment.
The abstract does not report several details that are often relevant for interpreting randomized trials: the rate of successful HP eradication in the active arm, adverse event frequencies, per‑protocol versus intention‑to‑treat population counts, or any subgroup analyses.
In this double‑blind randomized trial of HP eradication in HP‑positive patients with PD, a 14‑day triple therapy course did not produce statistically significant improvements in the predefined primary outcome (MDS‑UPDRS Part III in the ON state at 12 weeks) or in secondary measures of total motor and non‑motor burden and quality of life.
Based on the 12‑week results reported, the authors conclude that HP eradication therapy did not improve motor symptoms, non‑motor symptom burden, or quality of life and therefore do not support routine HP eradication as an adjunctive strategy for improving PD symptom control. Clinicians should note that these findings apply to the study population and the 12‑week time frame; the abstract does not provide longer‑term outcomes or detailed safety and eradication success data.
The trial was registered as CTRI/2019/04/018524. The investigators reported that the study was conducted in accordance with ethical standards (Declaration of Helsinki, ICH GCP), received Institutional Ethics Committee approval, and obtained written informed consent from participants. No conflicts of interest were declared on behalf of the authors.
Note: The summary and analysis above are limited to information provided in the PubMed/NCBI abstract. The abstract did not report certain trial details such as participant baseline characteristics, eradication confirmation rates, adverse events, or longer‑term follow‑up; those items would need to be confirmed by consulting the full published article.